At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 570 enrolled
Drug / intervention
20-valent pneumococcal conjugate vaccine (20vPnC) +2 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A PHASE 3, RANDOMIZED, DOUBLE BLIND TRIAL TO DESCRIBE THE SAFETY AND IMMUNOGENICITY OF 20 VALENT PNEUMOCOCCAL CONJUGATE VACCINE WHEN COADMINISTERED WITH A BOOSTER DOSE OF BNT162b2 IN ADULTS 65 YEARS OF AGE AND OLDER
In Brief
A Phase 3 clinical trial evaluating 20-valent pneumococcal conjugate vaccine (20vPnC), BNT162b2, and 1 other intervention for Pneumococcal Disease and 2 related conditions. Completed, enrolled 570 participants across 27 sites.
Detailed Summary
Study of the safety and immunogenicity of 20vPnC and a booster dose of BNT162b2 administered at the same visit or each vaccine given alone
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumococcal Disease, COVID-19, SARS-CoV-2 Infection
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20222023202420252026
First PostedMay 2021
Enrollment StartMay 2021
Primary CompletionDec 2021
TodayJul 2026
First PostedMay 14, 2021
Enrollment StartMay 20, 2021
Primary CompletionDec 8, 2021
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 5.1 years ago
Interventions
20-valent pneumococcal conjugate vaccine (20vPnC)biological
20-valent pneumococcal conjugate vaccine (20vPnC)
BNT162b2biological
RNA-based SARS-CoV-2 vaccine (BNT162b2)
Salineother
Normal saline for injection